Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.49 |
| ▸ | PPARG | P37231 | 6/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15240366 | 1.00 | PPARA (0.49) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL347259 | 0.90 | CTSS (0.48) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL347258 | 0.90 | CTSS (0.48) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL18614278 | 0.90 | CTSS (0.48) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL1515640 | 0.90 | CTSS (0.48) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL355405 | 0.90 | CTSS (0.48) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL23991234 | 0.87 | CTSS (0.46) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL1360500 | 0.86 | CTSK (0.51) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL66303 | 0.86 | CTSK (0.51) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL66302 | 0.86 | CTSK (0.51) | PPARAPPARGACECTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022109363-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109363-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220162217-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2011-05-05 | — | — | US | disclosed |
| US-7893067-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-20110039862-A1 | Protease Inhibitors | MEDIVIR AB (SE) | 2011-02-17 | — | — | US | disclosed |
| WO-2010034788-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034789-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034790-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-04-01 | — | — | WO | disclosed |
| EP-2167507-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090023748-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000877-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008114054-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | PPARA 4668/4885PPARG 3943/4885ACE 519/4885 |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | PPARA 794/4885PPARG 1989/4885ACE 1/4885 |
| US-20090023748-A1 | Cysteine Protease Inhibitors | CTSK, CTSL, CTSV | PPARA 4668/4885PPARG 3943/4885ACE 519/4885 |
| US-20110039862-A1 | Protease Inhibitors | CTSK, CTSF, CTSS | PPARA 4224/4885PPARG 3363/4885ACE 311/4885 |
| US-20220162217-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | PPARA 992/4885PPARG 2193/4885ACE 1/4885 |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | PPARA 849/4885PPARG 2118/4885ACE 1/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | PPARA 4208/4885PPARG 4358/4885ACE 77/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | PPARA 4657/4885PPARG 4610/4885ACE 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.